阿普斯特在中国获批治疗银屑病！

Apremilast works by dose-dependently inhibiting the release of tumor necrosis factor (TNF)-α from human synoviocytes and is a novel oral small molecule phosphodiesterase 4 (PDE4) inhibitor. The time to obtain approval for marketing from the National Medical Products Administration (NMPA) of China is August 16, 2021. This medicine is primarily used to treat adults with active psoriatic arthritis and psoriasis.

In 3 experimental studies, 1493 adult patients with PSA were randomized to receive placebo and Apremilast. The results showed that the proportion of ACR20 response patients in the 16th week of patients taking Apremilast was significantly higher than that in the placebo group. In the PSA-1 study, the Apremilast 30 mg, bid + DMARD group was 38%. In the PSA-2 study, the Apremilast group was 32%. In the study PSA-3, the Apremilast group was 41%, while in the placebo group PSA-1 Among them, 19% in the placebo + DMARDs group; 19% in the placebo group in Study PSA-2; and 18% in the placebo group in Study PSA-3. This shows that Apremilast is effective in treating PSA and the adverse effects are within acceptable limits. Apremilast has good selectivity, wide application, oral administration, convenient administration, low recurrence rate, good safety, single administration, accurate efficacy, short half-life, high tolerance, and has been trusted by many patients.

In March 2014, Apremilast was approved for marketing in the United States for the first time. Apremilast was originally developed by Celgene, a subsidiary of Bristol-Myers Squibb (BMS). Amgen announced in August 2019 that it had acquired the global rights of Apremilast. Apremilast is the first oral drug approved for the treatment of psoriasis in the past 20 years. According to current trials, during the 16 weeks of the study, the efficacy of Apremilast was comparable to that of Enbrel, with no significant difference between the two.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: